Measles Vaccine Market By Vaccine Type (Live Attenuated Measles Vaccine, Measles-Mumps-Rubella (MMR) Vaccine, Measles-Rubella (MR) Vaccine, Measles Vaccine for Adults) , By Distribution Channel (Hospitals & Clinics, Retail Pharmacies, Government Immunization Programs), By End-User (Pediatric Population, Adult Population, High-Risk Groups), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2024-2033
-
47125
-
June 2024
-
300
-
-
This report was compiled by Trishita Deb Trishita Deb is an experienced market research and consulting professional with over 7 years of expertise across healthcare, consumer goods, and materials, contributing to over 400 healthcare-related reports. Correspondence Team Lead- Healthcare Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
Report Overview
The Measles Vaccine Market was valued at USD 1.4 Billion in 2023. It is expected to reach USD 2.7 Billion by 2033, with a CAGR of 6.8% during the forecast period from 2024 to 2033.
The Measles Vaccine Market encompasses the global production, distribution, and sales of vaccines designed to prevent measles, a highly contagious viral infection. This market is driven by government immunization programs, increasing healthcare awareness, and rising incidences of measles outbreaks. Key stakeholders include pharmaceutical companies, healthcare providers, and public health organizations. The market is characterized by robust R&D activities to improve vaccine efficacy and delivery methods.
The measles vaccine market is poised for significant growth, driven by ongoing vaccine formulations and delivery methods advancements. Notable developments include needle-free vaccines and microarray patches, which promise to enhance both efficacy and patient compliance. As these innovations progress from research to clinical application, they are expected to catalyze market expansion. Furthermore, improving vaccine access and education, particularly in underserved regions, presents a substantial opportunity to increase global vaccination rates. This is critical as measles continues to pose a significant public health threat, particularly in regions with low vaccination coverage.
Investments in healthcare infrastructure and an increased emphasis on preventive healthcare are additional factors anticipated to bolster the measles vaccine market. Governments, NGOs, and private sectors are forming strategic collaborations to enhance vaccine coverage and reduce measles incidence globally. These partnerships are essential in addressing logistical challenges and ensuring equitable distribution of vaccines.
As a result, the measles vaccine market is not only expected to grow in terms of revenue but also in its impact on global health outcomes. The convergence of innovation, infrastructure investment, and strategic collaboration underscores a dynamic period of transformation for the measles vaccine market, setting a robust foundation for long-term growth and public health improvement.
Key Takeaways
- Market Growth: The Measles Vaccine Market was valued at USD 1.4 Billion in 2023. It is expected to reach USD 2.7 Billion by 2033, with a CAGR of 6.8% during the forecast period from 2024 to 2033.
- By Vaccine Type: MMR vaccine dominated due to comprehensive disease coverage and efficiency.
- By Distribution Channel: Hospitals & Clinics dominated measles vaccine distribution due to trust and infrastructure.
- By End-User: The Pediatric Population dominated the Measles Vaccine Market.
- Regional Dominance: North America leads the measles vaccine market with a 35% share.
- Growth Opportunity: The global measles vaccine market is set for growth in 2024 due to rising cases and stringent regulations.
Driving factors
Increased Awareness and Education: Elevating Vaccination Rates and Market Demand
The primary driving force behind the growth of the measles vaccine market is the heightened awareness and education about the disease and its prevention. Public health campaigns and educational initiatives have significantly contributed to an increased understanding of the importance of vaccination. For instance, the World Health Organization (WHO) and UNICEF have been pivotal in promoting vaccination programs globally, which has led to higher vaccination coverage rates.
As a result, parents are more likely to ensure their children receive the measles vaccine, directly boosting market demand. Additionally, the dissemination of information regarding the severe complications associated with measles, such as encephalitis and pneumonia, has reinforced the necessity of vaccination. In regions with historically lower vaccination rates, targeted educational efforts have led to notable increases in uptake, further propelling market growth.
Advancements in Vaccine Technology: Enhancing Efficacy and Accessibility
Technological advancements in vaccine development have significantly contributed to the expansion of the measles vaccine market. Modern vaccine technologies, such as the development of combination vaccines (e.g., MMR—measles, mumps, and rubella), have improved the efficiency of immunization programs by reducing the number of injections required. These advancements not only enhance the convenience for patients but also improve compliance rates, especially in pediatric populations.
Innovations in vaccine storage and distribution, including the development of more stable formulations that do not require stringent cold chain logistics, have expanded the reach of vaccination programs to remote and resource-limited areas. For example, the introduction of lyophilized (freeze-dried) vaccines has made it easier to maintain vaccine potency in diverse climatic conditions, thereby increasing the global market penetration of measles vaccines.
Increased Funding for Vaccine Development: Accelerating Research and Global Immunization Efforts
The measles vaccine market has also benefited from a substantial increase in funding for vaccine development and distribution. Governments, international organizations, and private sector stakeholders have invested heavily in immunization initiatives. According to Gavi, the Vaccine Alliance, funding for immunization programs has significantly increased over the past decade, with billions of dollars allocated to ensuring wider vaccine coverage. This influx of financial resources has facilitated the development of new vaccines and the expansion of immunization infrastructure, including the training of healthcare workers and the establishment of vaccination centers.
Increased funding has also supported mass vaccination campaigns and emergency outbreak responses, ensuring that vaccines are rapidly deployed in areas experiencing measles outbreaks. This comprehensive financial support has been crucial in achieving higher immunization rates and controlling the spread of measles, thereby driving the growth of the measles vaccine market.
Restraining Factors
Public Perception and Acceptance: A Crucial Determinant in Measles Vaccine Market Expansion
Public perception and acceptance play a pivotal role in shaping the growth trajectory of the measles vaccine market. Despite the proven efficacy and safety of measles vaccines, vaccine hesitancy remains a significant challenge. This hesitancy is often fueled by misinformation and distrust in pharmaceutical companies and healthcare systems. For instance, a 2022 survey by the World Health Organization (WHO) indicated that vaccine confidence varies widely, with some regions reporting that over 30% of the population is hesitant to vaccinate their children against measles.
The impact of public perception extends beyond individual decisions; it influences policy-making and funding for vaccination programs. Countries with high vaccine acceptance, such as those in Scandinavia, report higher vaccination coverage and lower incidence of measles outbreaks. Conversely, in regions where vaccine skepticism is prevalent, such as parts of Europe and the United States, vaccination rates have dropped below the threshold needed for herd immunity, leading to a resurgence of measles cases.
Vaccine Efficacy and Duration of Immunity: Ensuring Long-Term Market Stability
The efficacy of the measles vaccine and the duration of immunity it provides are fundamental to the market's growth and stability. The measles vaccine is known for its high efficacy, with a single dose conferring approximately 93% immunity and two doses increasing this to about 97%. However, concerns about waning immunity and the need for booster doses can influence public confidence and vaccination strategies.
Recent studies have shown that immunity from the measles vaccine can last for several decades, though some individuals may experience a decline in antibody levels over time. This potential waning immunity necessitates continuous monitoring and, in some cases, the administration of booster doses to maintain population-wide immunity. The WHO and CDC recommend that children receive two doses of the vaccine, a regimen that has proven highly effective in preventing outbreaks.
By Vaccine Type Analysis
In 2023, The MMR vaccine dominated due to comprehensive disease coverage and efficiency.
In 2023, The Measles-Mumps-Rubella (MMR) vaccine held a dominant market position in the "By Vaccine Type" segment of the measles vaccine market. The MMR vaccine's prominence can be attributed to its comprehensive coverage, immunizing against three significant diseases simultaneously, thereby streamlining immunization schedules and increasing overall vaccination rates. This vaccine's widespread acceptance and use, particularly in pediatric vaccination programs globally, underscore its critical role in public health strategies.
The live attenuated measles vaccine, although effective, is generally utilized in regions with lower resources or specific outbreaks, offering a single-targeted approach. The Measles-Rubella (MR) vaccine caters to regions prioritizing rubella elimination alongside measles control, filling a niche but important role in specific immunization initiatives.
Furthermore, the introduction of measles vaccines for adults addresses the immunity gaps in adult populations, especially in areas with historical vaccination lapses or increased exposure risks. However, the MMR vaccine's multifaceted benefits and broad application across different age groups and regions have solidified its leading market position, reflecting both its efficacy and strategic importance in global vaccination programs.
By Distribution Channel Analysis
In 2023, Hospitals & Clinics dominated measles vaccine distribution due to trust and infrastructure.
In 2023, Hospitals & Clinics held a dominant market position in the By Distribution Channel segment of the Measles Vaccine Market. This prominence is attributed to the robust infrastructure, comprehensive healthcare services, and the trusted environment hospitals and clinics offer for vaccinations. Hospitals and clinics are often the primary touchpoints for immunizations, benefiting from established relationships with patients and integrated health record systems that facilitate efficient vaccine administration and follow-ups.
Retail Pharmacies also contribute significantly to the market, driven by their accessibility and convenience. These pharmacies often provide extended hours and are strategically located, making them a practical choice for individuals seeking quick and accessible vaccination services without the need for appointments.
Government Immunization Programs play a crucial role, particularly in reaching underserved populations and ensuring broad-based immunization coverage. These programs are typically funded and organized by public health authorities, providing free or low-cost vaccines to ensure high immunization rates and public health safety. The collaboration between government initiatives and healthcare providers ensures a comprehensive approach to measles vaccination, enhancing the overall reach and effectiveness of the immunization efforts across diverse population segments.
By End-User Analysis
In 2023, The Pediatric Population dominated the Measles Vaccine Market.
In 2023, The Pediatric Population held a dominant market position in the By End-User segment of the Measles Vaccine Market. This dominance is primarily attributed to the high immunization rates mandated by national and international health agencies targeting children, given their vulnerability to measles infections. Key drivers include robust government vaccination programs, school-entry immunization requirements, and widespread public health campaigns emphasizing early childhood vaccination. Additionally, pediatric healthcare providers play a critical role in ensuring adherence to vaccination schedules, further bolstering this segment's prominence.
The Adult Population segment, though smaller, has seen growth due to increased awareness of vaccine-preventable diseases and the rise of catch-up vaccination initiatives for unvaccinated adults. This trend is supported by travel vaccination requirements and occupational health mandates in specific industries.
High-risk groups, encompassing individuals with compromised immune systems, pregnant women, and healthcare workers, represent a vital segment due to their increased susceptibility to measles complications. Tailored vaccination programs and priority access to vaccines ensure this group's protection, reflecting a strategic focus on minimizing outbreaks and safeguarding public health. Collectively, these dynamics underscore the multifaceted approach to measles vaccination across different end-user segments.
Key Market Segments
By Vaccine Type
- Live Attenuated Measles Vaccine
- Measles-Mumps-Rubella (MMR) Vaccine
- Measles-Rubella (MR) Vaccine
- Measles Vaccine for Adults
By Distribution Channel
- Hospitals & Clinics
- Retail Pharmacies
- Government Immunization Programs
By End-User
- Pediatric Population
- Adult Population
- High-Risk Groups
Growth Opportunity
Rising Incidences of Measles Disease
The global measles vaccine market is poised for significant growth in 2024, driven primarily by the increasing incidences and prevalence of measles. Despite the availability of effective vaccines, measles outbreaks continue to occur worldwide, underscoring the need for robust vaccination programs.
The World Health Organization (WHO) reported a 79% increase in measles cases globally in the first two months of 2023 compared to the same period in 2022. This alarming rise highlights the urgent need for increased vaccine coverage, particularly in regions with low immunization rates. Consequently, this surge in cases presents a substantial opportunity for vaccine manufacturers to expand their reach and impact.
Regulatory Enhancements and Patient Safety
The regulatory landscape is also evolving to support the growth of the measles vaccine market. Governments and health organizations are implementing more stringent regulations to ensure vaccine safety and efficacy. These regulations are designed to enhance public trust in vaccination programs and mitigate the risk of vaccine hesitancy.
For instance, the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have both introduced rigorous guidelines for vaccine approval and post-market surveillance. These regulatory enhancements are expected to drive demand for high-quality vaccines, thereby creating opportunities for market players to invest in research and development to meet these standards.
Latest Trends
Single Manufacturer Dominance
In 2024, the measles vaccine market is expected to witness a pronounced shift toward single-manufacturer dominance. This trend emerges from recent consolidations and strategic acquisitions within the pharmaceutical industry, where leading companies have acquired smaller firms to consolidate market share. The resultant effect is a landscape where a handful of large manufacturers hold significant sway over vaccine supply and pricing. This concentration can lead to more efficient production and distribution networks but also raises concerns about market competition and accessibility, particularly in low-income regions. The dominance of single manufacturers can streamline regulatory approvals and quality control processes, enhancing vaccine reliability and availability.
Increased Production Capacity
Another significant trend is the increase in production capacity for measles vaccines. Spurred by the heightened global demand and the necessity to meet vaccination targets set by health organizations, manufacturers are investing heavily in expanding their production facilities. This surge in capacity is facilitated by advancements in biotechnology and manufacturing processes, enabling faster and more cost-effective vaccine production. Enhanced production capabilities are expected to mitigate supply shortages and reduce lead times, ensuring a more consistent and reliable vaccine supply chain.
Regional Analysis
North America leads the measles vaccine market with a 35% share.
The measles vaccine market is experiencing significant growth across various regions, driven by increasing immunization initiatives and heightened awareness about the disease's risks. In North America, the market is dominated by the United States, which holds a substantial share due to high vaccination coverage and robust healthcare infrastructure. The region accounts for approximately 35% of the global market, propelled by governmental policies and widespread public health campaigns aimed at eradicating measles.
Europe follows closely, with countries like Germany, France, and the UK leading the charge. The European market benefits from comprehensive vaccination programs and strong support from healthcare organizations. The region represents around 30% of the global market share, reflecting its commitment to public health and disease prevention.
In the Asia Pacific, the market is expanding rapidly, particularly in China and India, due to large population bases and increasing government expenditure on healthcare. The region holds about 25% of the global market share, driven by initiatives such as India's Universal Immunization Programme.
The Middle East & Africa region, although smaller in market size, is witnessing steady growth due to rising awareness and international support for vaccination drives. Similarly, Latin America, led by Brazil and Mexico, is enhancing its vaccination efforts, contributing approximately 10% to the global market share.
Key Regions and Countries
North America
- The US
- Canada
- Rest of North America
Europe
- Germany
- France
- The UK
- Spain
- Netherlands
- Russia
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- Singapore
- Thailand
- South Korea
- Vietnam
- India
- New Zealand
- Rest of Asia Pacific
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of the Middle East & Africa
Key Players Analysis
The global measles vaccine market in 2024 is characterized by robust competition among leading pharmaceutical companies, each leveraging unique strengths to secure market share. Key players such as GlaxoSmithKline (GSK), Sanofi-Pasteur, Merck, and Novartis are at the forefront, driven by extensive R&D capabilities and comprehensive vaccine portfolios. GSK and Merck, with their strong global distribution networks and historical expertise in vaccine development, continue to play pivotal roles in addressing both endemic and outbreak situations.
Sanofi-Pasteur and Pfizer are expanding their footprints through strategic collaborations and enhanced production capabilities. Sanofi's innovative approach and Pfizer's strong financial backing ensure their competitive edge. The Serum Institute of India, as the largest vaccine manufacturer by volume, significantly impacts the market with cost-effective solutions, especially in emerging economies.
China National Biotech Group is capitalizing on growing domestic demand and expanding international reach, while Bavarian Nordic and Emergent BioSolutions focus on specialized vaccines and bioterrorism preparedness, respectively. MedImmune, a subsidiary of AstraZeneca, is enhancing its vaccine portfolio through biotechnological advancements.
Johnson & Johnson and CSL Limited are leveraging their extensive pharmaceutical expertise and global operations to enhance vaccine accessibility. Collectively, these companies drive the market forward, addressing global health challenges through innovation, strategic alliances, and expanding access to lifesaving vaccines.
Market Key Players
- Gsk
- Sanofi-Pasteur
- Merck
- Novartis
- Pfizer
- Serum Institute Of India
- China National Biotech Group
- Bavarian Nordic
- Emergent Biosolutions
- MedImmune
- Johnson & Johnson
- Csl Limited
Recent Development
- In January 2024, The Measles and Rubella Initiative transitioned to the Measles & Rubella Partnership (M&RP) as part of the Immunization Agenda 2030 (IA2030). This transition aims to integrate the measles and rubella immunization strategies more closely with global health goals, addressing the significant increase in the number of unvaccinated children globally (World Health Organization (WHO)).
- In March 2024, Gavi announced new funding commitments aimed at increasing measles vaccine coverage in low-income countries. This funding is intended to support large-scale vaccination campaigns and strengthen routine immunization systems to prevent future outbreaks (UNICEF) (World Health Organization (WHO)).
- In February 2024, The World Health Organization (WHO) Strategic Framework WHO, in collaboration with partners such as UNICEF and Gavi, launched the Measles and Rubella Strategic Framework 2030. This initiative is part of the broader Immunization Agenda 2030 and seeks to significantly reduce measles and rubella cases and deaths by expanding vaccine coverage and addressing gaps in immunization (World Health Organization (WHO)).
Report Scope
Report Features Description Market Value (2023) USD 1.4 Billion Forecast Revenue (2033) USD 2.7 Billion CAGR (2024-2032) 6.8% Base Year for Estimation 2023 Historic Period 2016-2023 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Vaccine Type (Live Attenuated Measles Vaccine, Measles-Mumps-Rubella (MMR) Vaccine, Measles-Rubella (MR) Vaccine, Measles Vaccine for Adults) , By Distribution Channel (Hospitals & Clinics, Retail Pharmacies, Government Immunization Programs), By End-User (Pediatric Population, Adult Population, High-Risk Groups) Regional Analysis North America - The US, Canada, Rest of North America, Europe - Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe, Asia-Pacific - China, Japan, South Korea, India, New Zealand, Singapore, Thailand, Vietnam, Rest of Asia Pacific, Latin America - Brazil, Mexico, Rest of Latin America, Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa Competitive Landscape Gsk, Sanofi-Pasteur, Merck, Novartis, Pfizer, Serum Institute Of India, China National Biotech Group, Bavarian Nordic, Emergent Biosolutions, MedImmune, Johnson & Johnson, Csl Limited Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
-
- Gsk
- Sanofi-Pasteur
- Merck
- Novartis
- Pfizer
- Serum Institute Of India
- China National Biotech Group
- Bavarian Nordic
- Emergent Biosolutions
- MedImmune
- Johnson & Johnson
- Csl Limited